$695 | Single User
$1395 | Global License

Physician Views: As race to market intensifies, how expectant are cardiologists for PCSK9 inhibitor class?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 07 Aug 2014 | 144 | In Stock
Related Topics: FDA

Introduction

Scope



The race to successfully deliver a PCSK9 inhibitor to market for the treatment of hypercholesterolaemia intensified last week with Sanofi and Regeneron Pharmaceuticals unveiling a raft of new late-stage data for their antibody alirocumab.


Furthermore, via novel means (see ViewPoints: But what is an FDA priority review voucher actually worth? BioMarin finally puts a price tag on it), Sanofi and Regeneron appear to have closed the regulatory gap on Amgen, with the US biotech now expected to enjoy first-to-market status for its antibody evolocumab by only a matter of months, according to most estimates.


With Amgen expected to make its initial regulatory filings for evolocumab this quarter and Sanofi/Regeneron anticipating submissions for alirocumab by year end, 2015 is expected to see the PCSK9 class make its long awaited commercial debut – see also FirstWord Lists: Pharma's biggest pipeline drugs.


Regulatory and commercial uncertainties remain, however, with these issues primarily shaped by the demonstrated clinical profiles of both products based on an initial surrogate endpoint (LDL cholesterol reduction) and data from longer-term outcomes studies, which are not due to be published until 2018 onwards.


Although the suggestion that regulatory authorities will not approve products in the class until outcomes data is available have rescinded, debate centres on physician uptake during the first two years of availability based on LDL-C reduction (and the likely trend that usage will be heavily limited to harder to treat hypercholesterolaemia patients).


One potential overhang is data from Merck & Co.'s ongoing IMPROVE-IT study, which is evaluating the clinical benefit of Vytorin across 18000 patients. Should the study not demonstrate a benefit on outcomes (which many commentators and key opinion leaders believe is likely), will this have an impact on the FDA's willingness to approve PCSK9 inhibitors on LDL lowering alone and an impact on physician sentiment towards the PCSK9 class? The 'bull' argument is that LDL-C reduction is better understood than raised HDL levels and that Vytorin is unlikely to demonstrate such a high reduction in LDL-C.


Assuming approval is secured for both leading PCSK9 inhibitors without the requirement for outcomes data, there is limited differentiation between Amgen and Sanofi/Regeneron's products. One opportunity could stem from Amgen's more advanced development of once-monthly dosing (versus once every two weeks for Sanofi/Regeneron), although this requires a longer infusion process – a notable issue given that hypercholesterolaemia patients have typically been treated with oral therapies.


Puchase Reasons


To provide further insight into how the early PCSK9 inhibitor market may evolve we are polling US and EU5-based cardiologists. Specifically we are asking them...


  • Which dosing regimen (once every two-weeks, which requires 1mL dosing with an auto-injector device, once-every four-weeks dosing, which requires three 1mL injections, or once every four weeks, which required one 10 minute infusion with a pager-sized device) they expect to prove most favourable among patients?

  • Whether negative data from the ongoing IMPROVE-IT study would have negative implications on their potential usage of the PCSK9 inhibitor class?

  • To what percentage of statin-intolerant hypercholesterolaemia patients (not at LDL goal) they would anticipate prescribing a PCSK9 inhibitor to two years after launch?

  • To what percentage of HeFH patients would you anticipate prescribing a PCSK9 inhibitor to two years after launch?

  • Which dosing regimen (once every two-weeks, which requires 1mL dosing with an auto-injector device, once-every four-weeks dosing, which requires three 1mL injections, or once every four weeks, which required one 10 minute infusion with a pager-sized device) they expect to prove most favourable among patients?
  • Table of Contents
    for Physician Views: As race to market intensifies, how expectant are cardiologists for PCSK9 inhibitor class? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    144 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: As race to market intensifies, how expectant are cardiologists for PCSK9 inhibitor class? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...

    • 360i Research
    • 99Strategy
    • Allied Market Research
    • Asia Market Information & Development Co.
    • Azoth Analytics
    • BioInformant
    • Black Swan Analysis
    • Canadean
    • CBR Pharma Insights
    • CRI
    • Current Analysis
    • Current Partnering
    • Daedal Research
    • Data bridge
    • Delve Insight
    • DPI Research
    • FirstWord Pharma
    • Future Market Insights
    • GBI Research
    • Global Data
    • Global Markets Direct
    • Global Research and Data Services GRDS
    • GMR Data
    • HeyReport
    • HongChun
    • HTStec
    • ICD Research
    • iGATE Research
    • IMARC
    • Industry ARC
    • Inkwood Research
    • IQ4I
    • Jain PharmaBiotech
    • Kelly Scientific
    • La Merie
    • Lifescience Intellipedia
    • LP Information
    • Market Data Forecast
    • Market Research Future
    • Marketline
    • MarketsandMarkets
    • McDerson
    • MedMarket Diligence
    • Meticulous Research
    • MicroMarketMonitor
    • MIReports
    • Mordor Intelligence LLC
    • MP Advisors
    • Occams Business Research
    • Prof Research
    • Progressive Markets
    • ProGrow Pharma Partners
    • Renub
    • Research Impact
    • RNCOS
    • Rockville Research
    • S&P Consulting
    • StratisticsMRC
    • The Business Research Company
    • Triton Market Research
    • Venture Planning Group (VPG)